The company began public trading on NASDAQ under symbol NTBL in October 2023, following a merger with VBL Therapeutics, and is focusing on advancement of its proprietary Predictive Precision Medicines Platform (PPMP) with a therapeutic pipeline focused on cancer patients, particularly acute myeloid leukemia (AML). Notable Labs targets patients with cancer, particularly those with acute myeloid leukemia, aiming to improve treatment outcomes by identifying responsive patient subsets.
Cyborg Score Rationale
Notable Labs operates innovative AI-driven precision medicine technology with clinical validation and public market access (listed on NASDAQ in October 2023), but faces early commercialization stage challenges with minimal reported revenue ($313K as of June 2024) and small headcount (31 employees as of late 2025). The company has demonstrated platform validation through Phase 2 studies and partnership activities but remains largely pre-revenue.
Top Insights
AI-driven precision medicine platform (PPMP) combines multi-dimensional biological assays and machine learning to simulate patient cancer treatment responses and predict individual drug efficacy
Merged with public company VBL Therapeutics (October 2023) to gain market access and develop Volasertib as lead clinical-stage program in AML
Near-zero revenue generation ($313K trailing twelve months as of June 2024) despite clinical progress, indicating early commercialization stage
Two Phase 2 clinical programs underway with focus on AML treatment, positioning company as rare-disease focused precision oncology player
Named Competitors
Verge Genomics — AI-driven precision medicine for rare diseases
AbCellera Biologics — AI and computational biology for drug discovery
Relay Therapeutics — Structure-based drug discovery and development
Recent Developments
(October 2023) Closed merger transaction with VBL Therapeutics and commenced public trading on NASDAQ under ticker NTBL
(April 2024) Presented two posters at American Association for Cancer Research (AACR) Annual Meeting on PLK1 inhibitor volasertib and treatment response prediction in AML
(December 2025) Market capitalization reported at $966.00
Open the full interactive Notable Labs, Ltd. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.